Association between genetic polymorphisms of methylenetetrahydrofolate reductase and congenital heart disease in Slovak population
Authors:
M. Záhorec 1; D. Ilenčíková 2; S. Požgayová 2; P. Olejník 3; P. Škrak 1; Ľ. Kováčiková 1; L. Kovács 2; J. Mašura 3
Authors place of work:
Oddelenie anestéziológie a intenzívnej medicíny, Detské kardiocentrum, Národný ústav srdcových a cievnych chorôb, Bratislava
primárka doc. MUDr. Ľ. Kováčiková, PhD.
1; Laboratórium klinickej a molekulovej genetiky, II. detská klinika Lekárskej fakulty Univerzity Komenského a Detskej fakultnej nemocnice s poliklinikou, Bratislava
prednosta prof. MUDr. L. Kovács, DrSc., MPH
2; Klinika detskej kardiológie Lekárskej fakulty Univerzity Komenského, Detské kardiocentrum, Národný ústav srdcových cievnych chorôb, Bratislava
prednosta prof. MUDr. J. Mašura, CSc.
3
Published in the journal:
Čes-slov Pediat 2015; 70 (5): 267-272.
Category:
Original Papers
Summary
Background:
Maternal periconceptual folic acid supplementation is associated with decreased risk of congenital heart disease (CHD) in offspring. Methylenetetrahydrofolate reductase (MTHFR) gene 677 C→T and 1298 A→C polymorphisms influence folic acid metabolism and in some studies are associated with increased risk of CHD. We sought to determine periconceptual folic acid supplementation in Slovak mothers of offspring with CHD and to investigate association between MTHFR 677 C→T and 1298 A→C polymorphisms and CHD risk.
Methods:
Between 2011 and 2014, 204 children with CHD, 144 mothers of CHD cases and 144 controls were prospectively evaluated for MTHFR 677 C→T and 1298 A→C polymorphisms.
Results:
Among cases with CHD, the 677TT genotype tended to occur less frequently than in control group (OR=0.42, 95% CI 0.18–1.01; p=0.06). Analysis revealed reduced prevalence of 1298CT and 1298CC genotypes in mothers of CHD patients when compared to controls (OR=0.51, 95% CI 0.31–0.84; p=0.009 resp. OR=0.78, 95% CI 0.13–1.04; p=0.06).
Periconceptual supplementation of multivitamins with folic acid content was observed in 18.1 % of case mothers. Multivitamins intake increased to 67.4 % in this group after pregnancy was confirmed (p<0.0001). Maternal periconceptual smoking was associated with lower use of multivitamin supplements compared to non-smokers (6.5% vs. 21.8%; p=0.035).
Conclusion:
We found no evidence that embryonic or maternal MTHFR gene polymorphisms that directly cause lower levels of plasma folate are associated with increased risk of CHD in Slovak population. On the contrary, some of those polymorphisms occurred less frequently in CHD population. Periconceptual multivitamin supplementation was observed in less than one fifth of mothers.
Key words:
folic acid, congenital heart disease, methylenetetrahydrofolate reductase, gene polymorphism, prevention Z.
Zdroje
1. Botto LD. Epidemiology and prevention of congenital heart defects. In: Allen HD, Driscoll DJ et al (eds). Moss´s and Adams Heart Disease in Infants, Children and Adolescents. 8th ed. Philadelphia, USA: Lippincott Williams & Wilkins, 2013: 577–616.
2. Verkleij-Hagoort AC, de Vries JHM, Ursem NTC, et al. Dietary intake of B-vitamins in mothers born a child with congenital heart defect. Eur J Nutr 2006; 45: 478–486.
3. Šabová L, Kovács L. Kyselina listová a vrodené vývojové chyby. Pediatr Prax 2008; 1: 36–38.
4. Czeizel AE, Dudás I, Vereczkey A, et al. Folate deficiency and folic acid supplementation: the prevention of neural-tube defects and congenital heart defects. Nutrients 2013; 5: 4760–4775.
5. Czeizel AE, Dudás I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992; 327:1832–1835.
6. Yang QH, Botto LD, Gallagher M, et al. Prevalence and effects of gene-gene and gene-nutrient interactions on serum folate and serum total homocysteine concentrations in the United States: findings from the third National Health and Nutrition Examination Survey DNA Bank. Am J Clin Nutr 2008; 88: 232–246.
7. van der Put NM, Gabreëls F, Stevens EM, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 1998; 62: 1044–1051.
8. Wang W, Hou Z, Wang C, et al. Association between 5, 10-methylen-etetrahydrofolate reductase (MTHFR) polymorphisms and congenital heart disease: A meta-analysis. Meta Gene 2013; 1: 109–125.
9. Goldmuntz E, Woyciechowski S, Renstrom D, et al. Variants of folate metabolism genes and the risk of conotruncal cardiac defects. Circ Cardiovasc Genet 2008; 1: 126–132.
10. Mamasoula C, Prentice RR, Pierscionek T, et al. Association between C677T polymorphism of methylenetetrahydrofolate reductase and congenital heart disease. Circ Cardiovasc Genet 2013; 6: 347–353.
11. Brandalize APC, Bandinelli E, dos Santos PA, et al. Evaluation of C677T and A1298C polymorphisms of MTHFR gene as maternal risk factors for Down syndrome and congenital heart disease. Am J Med Genet 2009; 149A: 2080–2087.
12. Steegers-Theunissen RP, Twigt J, Pestinger V, et al. The periconceptional period, reproduction and long-term health of offspring: the importance of one-carbon metabolism. Hum Reprod Update 2013; 19: 640–655.
13. Moorman A, Webb S, Brown NA, et al. Development of the heart: (1) formation of the cardiac chambers and arterial trunks. Heart 2003; 89: 806–814.
14. Li D, Rozen R. Maternal folate deficiency affects proliferation, but not apoptosis, in embryonic heart. J Nutr 2006; 136: 1774–1778.
15. Botto LD, Mulinare J, Erickson JD. Do multivitamin or folic acid supplements reduce the risk for congenital heart defects? Evidence and gaps. Am J Med Genet 2003; 121A: 95–101.
16. Van Beynum IM, Kapusta L, Bakker MK, et al. Protective effect of periconceptional folic acid supplements on the risk of congenital heart defects: A registry-based case-control study in the northern Netherlands. Eur Heart J 2010; 31: 464–471.
17. Goh YI, Bollano E, Einarson TR, Koren G. Prenatal multivitamin supplementation and rates of congenital anomalies: a meta-analysis. J Obstet Gynaecol Can 2006; 28: 680–689.
18. Hernandez-Diaz S, Werner MM, Walker AM, et al. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000; 343: 1608–1614.
19. Verkleij-Hagoort A, Bliek J, Sayed-Tabatabaei F, et al. Hyperhomocysteinemia and MTHFR polymorphisms in association with orofacial clefts and congenital heart defects: a meta-analysis. Am J Med Genet A 2007; 143A: 952–960.
20. Hobbs CA, James SJ, Parsian A, et al. Congenital heart defects and genetic variants in the methylenetetrahydrofolate reductase gene. J Med Genet 2006; 43: 162–166.
21. Ray JG, Singh G, Burrows RF. Evidence for suboptimal use of periconceptional folic acid supplements globally. BJOG 2004; 111: 399–408.
22. Horn F, Sabova L, Pinterova E, et al. Prevention of neural tube defects by folic acid – awareness among women of childbearing age in Slovakia. Bratisl Lek Listy 2014; 115: 91–97.
23. Sabova L. Génové polymorfizmy metabolizmu kyseliny listovej v etiológii defektov neurálnej rúry a Downovho syndrómu. Bratislava: Univerzita Komenského, 2010: 84–87.
24. Ionescu-Ittu R, Marelli AJ, Mackie AS, et al. Prevalence of severe congenital heart disease after folic acid fortification of grain products: time trend analysis in Quebec, Canada. BMJ 2009; 338: b1673.
25. Crider KS, Bailey LB, Berry RJ. Folic acid food fortification – its history, effect, concerns, and future directions. Nutrients 2011; 3: 370–384.
26. Pfeiffer CM, Johnson CL, Jain RB, et al. Trends in blood folate and vitamin B12 concentrations in the United States, 1988–2004. Am J Clin Nutr 2007; 86: 718–727.
27. Peyvandi S, Rychik J, Zhang X, et al. Preconceptual folic acid use and recurrence risk counceling for congenital heart disease. Congenit Heart Dis 2014; Jul 24, doi: 10.1111/chd.12206. [Epub ahead of print].
28. Eurostat Press Office: Between 8% and 25% of adults are obese across Member states. [cit. 2014-05-05]. Dostupné na internete: http://ec.europa.eu/eurostat/documents/2995521/5032782/3-24112011-BP-EN.PDF/831f0ca4-7105-4045-9e25-604141ef5108.
29. Behunová J, Podracká Ľ. Rázštepy nervovej trubice – súčasné pohľady na etiopatogenézu a možnosti prevencie kyselinou listovou. Čes-slov Pediat 2008; 63: 38–46.
30. Behunova J, Klimcakova L, Zavadilikova E, et al. Methylenetetrahydrofolate reductase gene polymorphisms and neural tube defects epidemiology in the Slovak population. Birth Defects Res A Clin Mol Teratol 2010; 88: 695–700.
31. Junker R, Kotthoff S, Vielhaber H, et al. Infant methylenetetrahydrofolate reductase 677TT genotype is a risk factor for congenital heart disease. Cardiovasc Res 2001; 51: 251–254.
32. van Beynum IM, Kapusta L, den Heijer M, et al. Maternal MTHFR C>T is a risk factor for congenital heart defects: Effect modification by periconceptional folate supplementation. Eur Heart J 2006; 27: 981–987.
33. van Beynum IM, den Heijer M, Blom HJ, et al. The MTHFR 677C->T polymorphism and the risk of congenital heart defects: a literature review and meta-analysis. QJM 2007; 100: 743–753.
34. Sayin Kocakap BD, Sanli C, Cabuk F, et al. Association of MTHFR A1298C polymorphism with conotruncal heart disease. Cardiol Young 2014; 30: 1–6.
Štítky
Neonatology Paediatrics General practitioner for children and adolescentsČlánok vyšiel v časopise
Czech-Slovak Pediatrics
2015 Číslo 5
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
- The Importance of Limosilactobacillus reuteri in Administration to Diabetics with Gingivitis
Najčítanejšie v tomto čísle
- Metabolic bone disease of prematurity – review article
- Rare case of patient with DiGeorge syndrome and limbs anomalies: the benefit of SNP microarray analysis?
- Special topics in lung ultrasound in children
- Association between genetic polymorphisms of methylenetetrahydrofolate reductase and congenital heart disease in Slovak population